PPSS Group Launch Next Generation Body Armour Offering Previously Unthinkable Levels Of Protection
4.12.2019 16:30:00 EET | Business Wire | Press release
PPSS Group's next generation of high-performance body armour is taking personal protection to a completely new-found level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005491/en/
PPSS Group using carbon fibre composites technology for their latest development (Photo: Business Wire)
Thoroughly field tested, the body armour will be made available from Monday 06 January 2020. A demonstration of the body armour is available to view here.
Made from Auxilam™, a unique carbon fibre composite material, this latest body armour will protect the wearer from even the most vicious and brutal types of edged weapon and shanks imaginable.
Utilising a combination of the incredible strength of carbon fibre, the auxetic properties of Auxilam™ technology and some additional ‘top secret’ assets derived from the specially developed composite structure, this next generation of body armour offers a truly outstanding balance of weight, protection, performance and durability.
Comparing it with PPSS Group’s highly acclaimed polycarbonate-based stab resistant vests, the company is claiming a reduction of 19% in thickness (utilising a 3.9mm carbon fibre composite) and a 6.6% lower aerial density and reduced weight for its latest development.
Yet, it will be certified to KR2/SP2 according to the UK Home Office Body Armour Standard, as well as NIJ Level 2 (Stab & Spike) and VPAM K2/D2 meaning it will offer a truly significant higher level of knife, spike and needle protection.
Government agencies and security companies will be able to chose from an array of different styles, ranging from covert, overt to hi viz overt options.
Robert Kaiser, CEO of PPSS Group states: “Law Enforcement, Border Force, Immigration, Customs and Prison Officers are being attacked by criminals carrying and using knives, machetes, shanks, blunt objects and hypodermic needles every day.”
“Our key objective is to protect those men and women even more effectively. Using the very latest in technology and following extensive research and development, our latest body armour is now offering previously absolutely unthinkable levels of protection.”
“It also offers exceptional, VPAM certified protection from blunt objects, effectively reducing the risks of blunt force trauma injuries e.g. internal bleeding.”
The UK headquartered firm has been supplying countless of homeland security agencies in countries around the world with their widely respected polycarbonate-based stab resistant vests over the past ten years.
Please contact PPSS Group directly in case you have any questions in regards to this press release.
About PPSS Group:
PPSS Group is specialised in the development, manufacturing and supply of high-performance personal protective equipment, offering unrivalled protection from edged weapons, blunt force trauma and even human bites. PPSS Group’s social media presence: Facebook, LinkedIn, Twitter, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005491/en/
Contact information
Media Contact:
Ryan Vickers – Chief Development Officer (CDO)
E: info@ppss-group.com
T: +44 (0) 845 5193953
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom